By Maggie Ma, Director of Clinical Operations, China
The biopharmaceutical industry in China, like the rest of the world, was forced to swiftly adopt decentralized clinical trial (DCT) approaches to maintain progress during to the COVID-19 pandemic. And, like the rest of the world, its patients, investigators and sponsors were hopeful about the benefits of using these tools.
Two new surveys conducted by IQVIA in China found patients are overwhelmingly open to participating in fully decentralized as well as hybrid virtual trials, and to using wearables, electronic data collection and other digital tools as part of that experience.
Our surveys showed that sponsors, CROs and investigators were also ready to engage. They see DCTs as a way to help them recruit and retain patients in this increasingly competitive marketplace. However, they still have some concerns about logistics, the reliability of digital data collection, and the still evolving regulatory landscape.
The results of these surveys offer exciting insights into the perception of virtual trial adoption in China as well as cultural perceptions that could help shape DCT approaches there. Further, the results suggest that these models will continue to be an important part of the clinical research landscape long after COVID-19 is under control.